SCHEMBL2115290

SCHEMBL2115290

CC(N)c1cc2c(F)cc(F)cc2nc1N1CCNC(=O)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCH P24723 1/20 0.37
PRKCE Q02156 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GRIA1 P42261 4/20 0.36
LRRK2 Q5S007 1/20 0.35
OPRM1 P35372 2/20 0.35
OPRK1 P41145 2/20 0.35
OGFRL1 Q5TC84 2/20 0.35
OPRD1 P41143 1/20 0.35
SCN9A Q15858 1/20 0.35
DPP4 P27487 1/20 0.35
CACNG2 Q9Y698 1/20 0.34
SOS1 Q07889 1/20 0.33
GRM2 Q14416 1/20 0.33
PARP1 P09874 1/20 0.32
AOC3 Q16853 1/20 0.32
PRKD1 Q15139 1/20 0.32
GAK O14976 1/20 0.31
PRMT5 O14744 1/20 0.31
ALK Q9UM73 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2115287 1.00 PRKCH (0.37) PRKCHPRKCEKDM4EGRIA1LRRK2
SCHEMBL2115432 0.84 GRIA1 (0.38) PRKCHPRKCEKDM4EGRIA1OPRM1
SCHEMBL2115435 0.84 GRIA1 (0.38) PRKCHPRKCEKDM4EGRIA1OPRM1
SCHEMBL717872 0.79 PRKCH (0.38) PRKCHPRKCEKDM4EGRIA1LRRK2
SCHEMBL717871 0.79 PRKCH (0.38) PRKCHPRKCEKDM4EGRIA1LRRK2
SCHEMBL2115845 0.77 DPP4 (0.35) PRKCHPRKCEKDM4EGRIA1LRRK2
SCHEMBL2115835 0.77 DPP4 (0.35) PRKCHPRKCEKDM4EGRIA1LRRK2
SCHEMBL2113480 0.76 NCF1 (0.38) GRIA1
SCHEMBL14480684 0.76 SOS1 (0.37) PRKCHPRKCEKDM4EGRIA1LRRK2
SCHEMBL14480681 0.76 SOS1 (0.37) PRKCHPRKCEKDM4EGRIA1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors PI4KA, PDPK1, PIK3CA PRKCH 337/4885PRKCE 173/4885KDM4E 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.